Summary

Persistence Market Research has recently released a comprehensive report on the global Bispecific Antibodies Market. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.

Key Insights:

• Bispecific Antibodies Market Size (2024E): US$10.8 Bn
• Projected Market Value (2031F): US$101.7 Bn
• Global Market Growth Rate (CAGR 2024 to 2031): 43.7%

Bispecific Antibodies Market - Report Scope:

Bispecific antibodies are engineered therapeutic proteins designed to bind to two different antigens simultaneously. These innovative molecules offer the potential to improve targeted treatment efficacy and overcome limitations of traditional monoclonal antibodies. The bispecific antibodies market includes products used in oncology, immunology, and other therapeutic areas. Key applications span from cancer immunotherapy to autoimmune disease management. Market growth is driven by advancements in antibody engineering, increasing cancer prevalence, and a rising demand for personalized medicine.

Market Growth Drivers:

The global bispecific antibodies market is propelled by several key factors, including the rising incidence of cancer and other chronic diseases, which necessitate novel and effective treatment options. The advancement of bispecific antibody technology, including enhanced targeting and reduced off-target effects, is fueling market expansion. Additionally, the increasing adoption of bispecific antibodies in clinical trials and the growing investment by pharmaceutical companies in R&D contribute to market growth. Strategic partnerships between biopharmaceutical companies and research institutions further accelerate the development and commercialization of bispecific antibodies.

Market Restraints:

Despite promising growth prospects, the bispecific antibodies market faces challenges related to high development costs and complex manufacturing processes. The lengthy and costly drug approval process can delay product launches and impact market accessibility. Additionally, regulatory hurdles and the potential for adverse effects or immune responses pose risks that need to be managed carefully. These factors can limit market entry and affect the financial viability of bispecific antibody products, particularly for smaller biotech firms.

Market Opportunities:

The bispecific antibodies market presents significant growth opportunities driven by technological innovations and emerging therapeutic applications. The integration of bispecific antibodies with novel drug delivery systems and combination therapies offers new avenues for market expansion. Additionally, increasing investment in cancer research and personalized medicine provides opportunities for market players to develop targeted treatments with improved efficacy. The growing prevalence of autoimmune diseases and the expansion of bispecific antibodies into new therapeutic areas further stimulate market growth.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the bispecific antibodies market globally?
• Which therapeutic areas and indications are driving bispecific antibodies adoption?
• How are technological advancements reshaping the competitive landscape of the bispecific antibodies market?
• Who are the key players contributing to the bispecific antibodies market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global bispecific antibodies market?

Competitive Intelligence and Business Strategy:

Leading players in the global bispecific antibodies market, including Amgen Inc., Genmab A/S, and AbbVie Inc., focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest heavily in R&D to develop advanced bispecific antibody therapies, targeting various diseases and improving clinical outcomes. Collaborations with research institutions, pharmaceutical companies, and healthcare providers enhance market access and foster technological advancements. Emphasis on clinical trials, regulatory compliance, and patient-centered strategies is critical to driving market growth and maintaining leadership in the rapidly evolving bispecific antibodies landscape.

Key Companies Profiled:

• Amgen
• F. Hoffmann-La Roche Ltd
• Genentech
• Akeso, Inc.
• Janssen
• Taisho Pharmaceutical
• Immunocore
• MacroGenics, Inc
• CELGENE CORPORATION
• Sanofi
• AstraZeneca

Bispecific Antibodies Market Segmentation

By Indication
• Cancer
• Inflammatory & Autoimmune Disorder

By End User
• Pharmaceutical companies
• Biotechnology companies
• Research institutions
• Hospitals and clinics

By Region
• North America
• Europe
• Asia-Pacific
• the Middle East and Africa
• Latin America

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Bispecific Antibodies Market Snapshot, 2024-2031
1.2. Market Opportunity Assessment, 2024-2031, US$ Bn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Macro-Economic Factors
2.3.1. Global Sectorial Outlook
2.3.2. Global GDP Growth Outlook
2.3.3. Global Healthcare Spending Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
3.1. Regulatory Landscape
3.2. Value Chain Analysis
3.3. Key Deals and Mergers
3.4. PESTLE Analysis
3.5. Porter’s Five Force Analysis
4. Global Bispecific Antibodies Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
4.1. Key Highlights
4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Bn) Analysis and Forecast
4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2023
4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2023-2031
4.3. Global Bispecific Antibodies Market Outlook: Indication
4.3.1. Introduction / Key Findings
4.3.2. Historical Market Size (US$ Bn) Analysis, By Indication, 2019-2023
4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2031
4.3.3.1. Cancer
4.3.3.2. Inflammatory & Autoimmune Disorder
4.3.3.3. Others
4.4. Market Attractiveness Analysis: Indication
4.5. Global Bispecific Antibodies Market Outlook: End User
4.5.1. Introduction / Key Findings
4.5.2. Historical Market Size (US$ Bn) Analysis, By End User, 2019-2023
4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
4.5.3.1. Pharmaceutical companies
4.5.3.2. Biotechnology companies
4.5.3.3. Research institutions
4.5.3.4. Hospitals and clinics
4.6. Market Attractiveness Analysis: End User
5. Global Bispecific Antibodies Market Outlook: Region
5.1. Key Highlights
5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2023
5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2024-2031
5.3.1. North America
5.3.2. Europe
5.3.3. East Asia
5.3.4. South Asia and Oceania
5.3.5. Latin America
5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region
6. North America Bispecific Antibodies Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
6.1. Key Highlights
6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
6.2.1. By Country
6.2.2. By Indication
6.2.3. By End User
6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
6.3.1. U.S.
6.3.2. Canada
6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2031
6.4.1. Cancer
6.4.2. Inflammatory & Autoimmune Disorder
6.4.3. Others
6.5. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
6.5.1. Pharmaceutical companies
6.5.2. Biotechnology companies
6.5.3. Research institutions
6.5.4. Hospitals and clinics
6.6. Market Attractiveness Analysis
7. Europe Bispecific Antibodies Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
7.1. Key Highlights
7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
7.2.1. By Country
7.2.2. By Indication
7.2.3. By End User
7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
7.3.1. Germany
7.3.2. France
7.3.3. U.K.
7.3.4. Italy
7.3.5. Spain
7.3.6. Russia
7.3.7. Turkey
7.3.8. Rest of Europe
7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2031
7.4.1. Cancer
7.4.2. Inflammatory & Autoimmune Disorder
7.4.3. Others
7.5. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
7.5.1. Pharmaceutical companies
7.5.2. Biotechnology companies
7.5.3. Research institutions
7.5.4. Hospitals and clinics
7.6. Market Attractiveness Analysis
8. East Asia Bispecific Antibodies Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
8.1. Key Highlights
8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
8.2.1. By Country
8.2.2. By Indication
8.2.3. By End User
8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
8.3.1. China
8.3.2. Japan
8.3.3. South Korea
8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2031
8.4.1. Cancer
8.4.2. Inflammatory & Autoimmune Disorder
8.4.3. Others
8.5. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
8.5.1. Pharmaceutical companies
8.5.2. Biotechnology companies
8.5.3. Research institutions
8.5.4. Hospitals and clinics
8.6. Market Attractiveness Analysis
9. South Asia & Oceania Bispecific Antibodies Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
9.1. Key Highlights
9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
9.2.1. By Country
9.2.2. By Indication
9.2.3. By End User
9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
9.3.1. India
9.3.2. Southeast Asia
9.3.3. ANZ
9.3.4. Rest of South Asia & Oceania
9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2031
9.4.1. Cancer
9.4.2. Inflammatory & Autoimmune Disorder
9.4.3. Others
9.5. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
9.5.1. Pharmaceutical companies
9.5.2. Biotechnology companies
9.5.3. Research institutions
9.5.4. Hospitals and clinics
9.6. Market Attractiveness Analysis
10. Latin America Bispecific Antibodies Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
10.1. Key Highlights
10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
10.2.1. By Country
10.2.2. By Indication
10.2.3. By End User
10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
10.3.1. Brazil
10.3.2. Mexico
10.3.3. Rest of Latin America
10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2031
10.4.1. Cancer
10.4.2. Inflammatory & Autoimmune Disorder
10.4.3. Others
10.5. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
10.5.1. Pharmaceutical companies
10.5.2. Biotechnology companies
10.5.3. Research institutions
10.5.4. Hospitals and clinics
10.6. Market Attractiveness Analysis
11. Middle East & Africa Bispecific Antibodies Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
11.1. Key Highlights
11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
11.2.1. By Country
11.2.2. By Indication
11.2.3. By End User
11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
11.3.1. GCC Countries
11.3.2. Egypt
11.3.3. South Africa
11.3.4. Northern Africa
11.3.5. Rest of Middle East & Africa
11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2031
11.4.1. Cancer
11.4.2. Inflammatory & Autoimmune Disorder
11.4.3. Others
11.5. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
11.5.1. Pharmaceutical companies
11.5.2. Biotechnology companies
11.5.3. Research institutions
11.5.4. Hospitals and clinics
11.6. Market Attractiveness Analysis
12. Competition Landscape
12.1. Market Share Analysis, 2023
12.2. Market Structure
12.2.1. Competition Intensity Mapping By Market
12.2.2. Competition Dashboard
12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
12.3.1. Amgen
12.3.1.1. Overview
12.3.1.2. Segments and Products
12.3.1.3. Key Financials
12.3.1.4. Market Developments
12.3.1.5. Market Strategy
12.3.2. F. Hoffmann-La Roche Ltd
12.3.3. Genentech
12.3.4. Akeso, Inc.
12.3.5. Janssen
12.3.6. Taisho Pharmaceutical
12.3.7. Immunocore
12.3.8. MacroGenics, Inc
12.3.9. CELGENE CORPORATION
12.3.10. Sanofi
12.3.11. AstraZeneca
13. Appendix
13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations